These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23322007)

  • 41. Bringing DNA vaccines closer to commercial use.
    Carvalho JA; Prazeres DM; Monteiro GA
    IDrugs; 2009 Oct; 12(10):642-7. PubMed ID: 19790015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gaps in knowledge and prospects for research of adjuvanted vaccines.
    Seder R; Reed SG; O'Hagan D; Malyala P; D'Oro U; Laera D; Abrignani S; Cerundolo V; Steinman L; Bertholet S
    Vaccine; 2015 Jun; 33 Suppl 2():B40-3. PubMed ID: 26022566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Emerging Role of Digital Technologies in Early Clinical Development.
    Krishna R
    Clin Pharmacol Ther; 2018 Jan; 103(1):39-41. PubMed ID: 29105745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?
    De Groot AS; Einck L; Moise L; Chambers M; Ballantyne J; Malone RW; Ardito M; Martin W
    Hum Vaccin Immunother; 2013 Sep; 9(9):1877-84. PubMed ID: 23877094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing the use of CROs by academia and small companies.
    Lane RF; Friedman LG; Keith C; Braithwaite SP; Frearson JA; Lowe DA; Longo FM; Refolo LM; Watterson DM; Tsaioun K; Shineman DW; Fillit HM
    Nat Rev Drug Discov; 2013 Jul; 12(7):487-8. PubMed ID: 23812255
    [No Abstract]   [Full Text] [Related]  

  • 46. Plant-made vaccines in support of the Millennium Development Goals.
    Penney CA; Thomas DR; Deen SS; Walmsley AM
    Plant Cell Rep; 2011 May; 30(5):789-98. PubMed ID: 21243362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
    Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
    Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Upcycling drugs for brain-related diseases: a sustainable future for targeted drug delivery.
    de Boer M; Visser CC; Gaillard PJ
    Ther Deliv; 2013 Apr; 4(4):435-8. PubMed ID: 23557284
    [No Abstract]   [Full Text] [Related]  

  • 49. Taking aim at novel vaccines market.
    Awasthi S
    Hum Vaccin; 2009 Oct; 5(10):654-7. PubMed ID: 19855156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Agility in adversity: Vaccines on Demand.
    De Groot AS; Moise L; Olive D; Einck L; Martin W
    Expert Rev Vaccines; 2016 Sep; 15(9):1087-91. PubMed ID: 27389971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vector-based genetically modified vaccines: Exploiting Jenner's legacy.
    Ramezanpour B; Haan I; Osterhaus A; Claassen E
    Vaccine; 2016 Dec; 34(50):6436-6448. PubMed ID: 28029542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Translation of an experimental oral vaccine formulation into a commercial product.
    Carter KC; Ferro VA; Alexander J; Mullen AB
    Methods; 2006 Feb; 38(2):65-8. PubMed ID: 16406571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An overview of FDA-approved vaccines & their innovators.
    Griesenauer RH; Kinch MS
    Expert Rev Vaccines; 2017 Dec; 16(12):1253-1266. PubMed ID: 28931331
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status.
    Jadhav SS; Gautam M; Gairola S
    Biologicals; 2009 Jun; 37(3):165-8. PubMed ID: 19328010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Availability of quality vaccines: policies of a non-government organization.
    Poore P
    Vaccine; 1992; 10(13):958-60. PubMed ID: 1471421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New vaccine technologies.
    Wood DJ
    Dev Biol (Basel); 2002; 111():285-90. PubMed ID: 12678251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing Countries Vaccine Manufacturers Network: doing good by making high-quality vaccines affordable for all.
    Pagliusi S; Leite LC; Datla M; Makhoana M; Gao Y; Suhardono M; Jadhav S; Harshavardhan GV; Homma A
    Vaccine; 2013 Apr; 31 Suppl 2():B176-83. PubMed ID: 23598479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gates launches $1bn vaccine initiative to target emerging infectious diseases.
    Gulland A
    BMJ; 2017 Jan; 356():j330. PubMed ID: 28104583
    [No Abstract]   [Full Text] [Related]  

  • 60. New Vaccines for the World's Poorest People.
    Hotez PJ; Bottazzi ME; Strych U
    Annu Rev Med; 2016; 67():405-17. PubMed ID: 26356803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.